WO2003052091A8 - Growth factor modified protein matrices for tissue engineering - Google Patents

Growth factor modified protein matrices for tissue engineering

Info

Publication number
WO2003052091A8
WO2003052091A8 PCT/US2002/041114 US0241114W WO03052091A8 WO 2003052091 A8 WO2003052091 A8 WO 2003052091A8 US 0241114 W US0241114 W US 0241114W WO 03052091 A8 WO03052091 A8 WO 03052091A8
Authority
WO
WIPO (PCT)
Prior art keywords
matrix
heparin
drug
protein
regeneration
Prior art date
Application number
PCT/US2002/041114
Other languages
French (fr)
Other versions
WO2003052091A1 (en
Inventor
Jeffrey A Hubbell
Matthias Lutolf
Jason Schense
Anna Jen
Original Assignee
Eth Zuerich
Univ Zuerich
Jeffrey A Hubbell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/024,918 external-priority patent/US20020168718A1/en
Priority claimed from PCT/EP2002/012458 external-priority patent/WO2003040235A1/en
Priority claimed from US10/323,046 external-priority patent/US7601685B2/en
Priority to KR1020047009700A priority Critical patent/KR100925070B1/en
Priority to DE60225185T priority patent/DE60225185T2/en
Priority to EP02792510A priority patent/EP1465989B1/en
Priority to AU2002358272A priority patent/AU2002358272B2/en
Priority to JP2003552958A priority patent/JP4560291B2/en
Application filed by Eth Zuerich, Univ Zuerich, Jeffrey A Hubbell filed Critical Eth Zuerich
Priority to MXPA04006021A priority patent/MXPA04006021A/en
Priority to CA002470419A priority patent/CA2470419A1/en
Priority to BRPI0215192A priority patent/BRPI0215192B8/en
Publication of WO2003052091A1 publication Critical patent/WO2003052091A1/en
Publication of WO2003052091A8 publication Critical patent/WO2003052091A8/en
Priority to NO20043031A priority patent/NO331726B1/en
Priority to HK04110140A priority patent/HK1067147A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/225—Fibrin; Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Proteins are incorporated into protein or polysaccharide matrices for use in tissue repair, regeneration and/or remodeling and/or drug delivery. The proteins can be incorporated so that they are released by degradation of the matrix, by enzymatic action and/or diffusion. As demonstrated by the examples, one method is to bind heparin to the matrix by either covalent or non-covalent methods, to form a heparin-matrix. The heparin then non-covalently binds heparin-binding growth factors to the protein matrix. Alternatively, a fusion protein can be constructed which contains a crosslinking region such as a factor XIIIa substrate and the native protein sequence. Incorporation of degradable linkages between the matrix and the bioactive factors can be particularly useful when long-term drug delivery is desired, for example in the case of nerve regeneration, where it is desirable to vary the rate of drug release spatially as a function of regeneration, e.g. rapidly near the living tissue interface and more slowly farther into the injury zone. Additional benefits include the lower total drug dose within the delivery system, and spatial regulation of release which permits a greater percentage of the drug to be released at the time of greatest cellular activity.
PCT/US2002/041114 2001-12-18 2002-12-18 Growth factor modified protein matrices for tissue engineering WO2003052091A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
BRPI0215192A BRPI0215192B8 (en) 2001-12-18 2002-12-18 fusion peptide, kit and matrix comprising the same, and method for creating a matrix
CA002470419A CA2470419A1 (en) 2001-12-18 2002-12-18 Growth factor modified protein matrices for tissue engineering
MXPA04006021A MXPA04006021A (en) 2001-12-18 2002-12-18 Growth factor modified protein matrices for tissue engineering.
DE60225185T DE60225185T2 (en) 2001-12-18 2002-12-18 GROWTH FACTOR-MODIFIED PROTEIN MATRICES FOR TISSUE ENGINEERING
EP02792510A EP1465989B1 (en) 2001-12-18 2002-12-18 Growth factor modified protein matrices for tissue engineering
AU2002358272A AU2002358272B2 (en) 2001-12-18 2002-12-18 Growth factor modified protein matrices for tissue engineering
JP2003552958A JP4560291B2 (en) 2001-12-18 2002-12-18 Growth factor-modified protein matrix for tissue manipulation
KR1020047009700A KR100925070B1 (en) 2001-12-18 2002-12-18 Growth factor modified protein matrices for tissue engineering
NO20043031A NO331726B1 (en) 2001-12-18 2004-07-15 Fusion peptide comprising a first domain comprising parathyroid hormone (PTH) and a second domain comprising a substrate domain, set and matrix comprising the fusion peptide, and methods for producing a matrix
HK04110140A HK1067147A1 (en) 2001-12-18 2004-12-22 Growth factor modified protein matrices for tissueengineering

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10/024,918 2001-12-18
US10/024,918 US20020168718A1 (en) 1997-04-03 2001-12-18 Enzyme-mediated modification of fibrin for tissue engineering
EPPCT/EP02/12458 2002-11-07
PCT/EP2002/012458 WO2003040235A1 (en) 2001-11-07 2002-11-07 Synthetic matrix for controlled cell ingrowth and tissue regeneration
US10/323,046 US7601685B2 (en) 1998-08-27 2002-12-17 Growth factor modified protein matrices for tissue engineering
US10/325,021 2002-12-18

Publications (2)

Publication Number Publication Date
WO2003052091A1 WO2003052091A1 (en) 2003-06-26
WO2003052091A8 true WO2003052091A8 (en) 2003-08-07

Family

ID=27807134

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/041114 WO2003052091A1 (en) 2001-12-18 2002-12-18 Growth factor modified protein matrices for tissue engineering

Country Status (9)

Country Link
JP (2) JP4560291B2 (en)
AT (1) ATE386545T1 (en)
AU (2) AU2002358272B2 (en)
BR (1) BRPI0215192B8 (en)
CA (1) CA2470419A1 (en)
DE (1) DE60225185T2 (en)
ES (1) ES2301697T3 (en)
MX (1) MXPA04006021A (en)
WO (1) WO2003052091A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8961947B2 (en) 2007-04-13 2015-02-24 Kuros Biosurgery Ag Polymeric tissue sealant

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351423B2 (en) 2004-09-01 2008-04-01 Depuy Spine, Inc. Musculo-skeletal implant having a bioactive gradient
EP1862170B1 (en) 2004-12-10 2012-03-14 Straumann Holding AG Enamel formulation with amelogenin
SE0403014D0 (en) 2004-12-10 2004-12-10 Straumann Holding Ag New protein formulation
WO2006064381A2 (en) * 2004-12-10 2006-06-22 Straumann Holding Ag Protein formulation
EP1828244A2 (en) * 2004-12-22 2007-09-05 Kuros Biosurgery AG Michael-type addition reaction functionalised peg hydrogels with factor xiiia incorporated biofactors
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
KR20070108170A (en) * 2005-01-06 2007-11-08 쿠로스 바이오서저리 아게 Supplemented matrices for the repair of bone fractures
WO2006073711A2 (en) 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
CA2930681C (en) 2007-04-09 2019-10-15 The Board Of Trustees Of The University Of Arkansas Fusion protein of collagen-binding domain and parathyroid hormone
US20100284919A1 (en) * 2007-10-12 2010-11-11 Kuros Biosurgery Ag Injectable Radio-Opaque Compositions for Tissue Augmentation
EP2279021B1 (en) 2008-04-18 2013-02-13 Kuros Biosurgery AG Dispensing device, kit containing the device, and method of operating the device
WO2011025957A2 (en) * 2009-08-28 2011-03-03 Ecole Polytechnique Federal De Lausanne Tg-aprotinin fusion proteins and matrices thereof
JP6120778B2 (en) * 2011-02-03 2017-04-26 ノースイースタン ユニヴァーシティ Methods and compositions for highly specific capture and release of biological material
EP2686027B1 (en) 2011-03-16 2021-05-05 Kuros Biosurgery AG Pharmaceutical formulation for use in spinal fusion
CA2859412C (en) 2011-12-14 2021-05-25 The Board Of Trustees Of The University Of Arkansas Delivery of therapeutic agents using bacterial collagen-binding polypeptide segments
US9526765B2 (en) 2012-02-09 2016-12-27 The Kitasato Institute Delivery of therapeutic agents by a collagen binding protein
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
ES2651113T3 (en) 2012-06-25 2018-01-24 The Brigham And Women's Hospital, Inc. Targeted therapeutic treatments
WO2017042301A1 (en) * 2015-09-09 2017-03-16 ETH Zürich Injectable macroporous hydrogels
US11624060B2 (en) 2017-02-10 2023-04-11 The Board Of Trustees Of The University Of Arkansas Collagen-binding agent compositions and methods of using the same
EP3536353A1 (en) 2018-03-09 2019-09-11 Kuros Biosurgery AG Method and kits for producing a fibrin matrix

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171670A (en) * 1989-05-12 1992-12-15 The General Hospital Corporation Recombinant dna method for production of parathyroid hormone
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
CA2237296C (en) * 1995-11-16 2008-10-07 Boehringer Mannheim Gmbh Process for the preparation of peptides by way of streptavidin fusion proteins
BR9813740A (en) * 1997-12-18 2000-10-10 Lilly Co Eli Crystalline teriparatide
CA2359318C (en) * 1999-02-01 2009-06-30 Donald Elbert Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
JP2001190280A (en) * 1999-02-19 2001-07-17 Terumo Corp Collagen-binding physiologically active polypeptide

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8961947B2 (en) 2007-04-13 2015-02-24 Kuros Biosurgery Ag Polymeric tissue sealant
US9180222B2 (en) 2007-04-13 2015-11-10 Kuros Biosurgery Ag Polymeric tissue sealant

Also Published As

Publication number Publication date
AU2002358272A1 (en) 2003-06-30
JP4560291B2 (en) 2010-10-13
DE60225185D1 (en) 2008-04-03
DE60225185T2 (en) 2009-02-19
AU2002358272B2 (en) 2009-01-22
ATE386545T1 (en) 2008-03-15
WO2003052091A1 (en) 2003-06-26
JP2009102383A (en) 2009-05-14
BRPI0215192B8 (en) 2021-07-27
AU2009201588A1 (en) 2009-05-14
BRPI0215192B1 (en) 2016-03-22
AU2009201588B2 (en) 2011-02-24
ES2301697T3 (en) 2008-07-01
CA2470419A1 (en) 2003-06-26
MXPA04006021A (en) 2005-08-19
BR0215192A (en) 2005-04-26
JP2005517658A (en) 2005-06-16

Similar Documents

Publication Publication Date Title
WO2003052091A8 (en) Growth factor modified protein matrices for tissue engineering
WO2001083522A3 (en) Growth factor modified protein matrices for tissue engineering
Pan et al. Advances in the repair of segmental nerve injuries and trends in reconstruction
Thomopoulos et al. Enhanced flexor tendon healing through controlled delivery of PDGF‐BB
Ramburrun et al. A review of bioactive release from nerve conduits as a neurotherapeutic strategy for neuronal growth in peripheral nerve injury
WO2003065881A3 (en) Medical device with coating that promotes endothelial cell adherence and differentiation
ATE392907T1 (en) BIOABSORBABLE COMPOSITE MATERIALS MADE OF DERIVATIZED HYALURONIC ACID
WO2005012364A3 (en) Complex matrix for biomedical use
Gelberman et al. The early effects of sustained platelet-derived growth factor administration on the functional and structural properties of repaired intrasynovial flexor tendons: an in vivo biomechanic study at 3 weeks in canines
Hao et al. Collagen/heparin bi‐affinity multilayer modified collagen scaffolds for controlled bFGF release to improve angiogenesis in vivo
RU2010125705A (en) GEL POLYSACCHARIDE COMPOSITIONS AND METHODS FOR LONG-TERM DELIVERY OF MEDICINES
WO2007062060A3 (en) Methods and compositions using substance p to promote wound healing
WO2007002554A3 (en) Methods and systems for treating injured cardiac tissue
JP2008508959A5 (en)
BRPI0406606A (en) Pharmaceutical composition comprising an immunoglobulin fc region as a carrier
Doǧan et al. Controlled release of EGF and bFGF from dextran hydrogels in vitro and in vivo
Chinen et al. Action of microparticles of heparin and alginate crosslinked gel when used as injectable artificial matrices to stabilize basic fibroblast growth factor and induce angiogenesis by controlling its release
Hettiaratchi et al. Modulated protein delivery to engineer tissue repair
WO2006060309A3 (en) Compositions and methods for ex vivo preservations of organs
Mantripragada et al. Injectable chitosan microparticles incorporating bone morphogenetic protein‐7 for bone tissue regeneration
WO2005122734A3 (en) Nanosphere/microsphere delivery system for the treatment of spinal cord injury
Nilasaroya et al. Heparin‐functionalized hydrogels as growth factor‐signaling substrates
CN109224128A (en) Load the slow-releasing system and its construction method of the collagen scaffold of bioactie agent
Chang Studies in flexor tendon reconstruction: biomolecular modulation of tendon repair and tissue engineering
Munoz‐Pinto et al. Evaluation of late outgrowth endothelial progenitor cell and umbilical vein endothelial cell responses to thromboresistant collagen‐mimetic hydrogels

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 26/2003 UNDER (30) REPLACE "17 DECEMBER 2002 (17.12.2002)" BY "18 DECEMBER 2002 (18.12.2002)"

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2470419

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003552958

Country of ref document: JP

Ref document number: 2002358272

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/006021

Country of ref document: MX

Ref document number: 1020047009700

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002792510

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002792510

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002792510

Country of ref document: EP